Literature DB >> 21489935

A retrospective review of basilic and cephalic vein-based fistulas.

Anantha K Ramanathan1, Nader D Nader, Maciej L Dryjski, Hasan H Dosluoglu, Gregory S Cherr, G Richard Curl, Alan S Kuritzky, Linda M Harris.   

Abstract

This study compares outcomes of basilic and cephalic vein fistulas for hemodialysis. A retrospective review of arteriovenous fistulas in a university hospital system was performed using charts and hemodialysis records. Patency and demographic data were assessed with life table analysis. One hundred fifty-six patients (88 males; 68 females) underwent creation of 172 autogenous fistulas (mean age 61 years; mean follow-up 78 weeks). There were 101 basilic vein transpositions and 71 cephalic vein fistulas. Primary patency did not differ significantly, while assisted primary patency was significantly better for basilic vein fistulas at one year (73% versus 53%: P = 0.024). Secondary patency was significantly better for basilic fistulas through three years (58% versus 52%; P = 0.027). Primary failure (thrombosis before access or failed maturation) was significantly higher for cephalic than basilic fistulas (28% versus 13%; P = 0.01). Maturation time, usage time and complications were not significantly significant. Thirty-three (33%) basilic vein-based fistulas and 12 (17%) cephalic vein fistulas required revision during follow-up. Basilic vein-based fistulas perform as well as or better than cephalic vein-based fistulas in terms of patency, maturation time, and usage time and complication rates, though requiring more re-interventions.

Entities:  

Mesh:

Year:  2011        PMID: 21489935     DOI: 10.1258/vasc.2010.oa0228

Source DB:  PubMed          Journal:  Vascular        ISSN: 1708-5381            Impact factor:   1.285


  1 in total

1.  Long-term patency of autogenous saphenous veins vs. PTFE interposition graft for prosthetic hemodialysis access.

Authors:  Barçın Özcem; Kamil Gülşen; Levent Cerit; Cenk Conkbayır
Journal:  Anatol J Cardiol       Date:  2015-03       Impact factor: 1.596

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.